Possible covid-19 vaccine from China shows promise in trials-otgnewsupdate

Wednesday, June 10, 2020
Possible covid-19 vaccine from China shows promise in trials-otgnewsupdate

BEIJING (Reuters) - A 19-vaccine, developed by Chinese researchers, did not promise to test monkeys, stimulate antibodies and increase safety measures, researchers say. A human trial involving more than one participant is underway.

In an article published online by the medical journal Cell on Saturday, the researchers said that the vaccine candidate, called BBIBP-Curio, encouraged high levels of neutral antibodies. Which can prevent the virus from infecting the cells of monkeys, mice, guinea pigs and rabbits.

"These findings support further diagnosis of BBIBP-CorV in clinical trials," the researchers said in the article.

BBB-Karvi, affiliated with the state-owned National Pharmaceutical Group (Synoform) developed by the Beijing Institute of Biological Products, is one of five candidates that China is testing in humans.

More than 100 possible COVID-19 vaccines are in various stages of development worldwide. AstraZeneca, Pfizer, Biotech, Johnson & Johnson, Merck, Moderna, Sanofi and Chinese Canoe Biologics are currently developing the fronts involved in human trials.

In addition to producing immune responses in animals as well as appearing to be safe and viable, BBIBP - has not been shown to stimulate chorio antibodies that can exacerbate infection - a phenomenon that increases antibody-dependent ( Known as ADE), the researchers said, although not necessarily a guarantee that ADE will not occur in human tests.

In addition to BBIBP-Corvi, Sinofirm, which has invested 1 billion yuan (14 141.40 million) in vaccine projects, is examining another vaccine candidate developed by the Wuhan-based unit in humans. ۔ Both shots have been given to more than 2,000 people in clinical trials.


OTG Newz